A biopharmaceutical company at the transition from pure research and development to its own production works differently from one that only develops. This company was making exactly that move — and ran into a gap that is typical of this growth phase: tracking products across the value chain was done entirely by hand. No automated process existed. What is still manageable in the development phase becomes a structural risk once you produce in-house — for delivery reliability, for transparency in the supply chain, and for the effort tied up week after week in manual tracking.
This is precisely where what we call the ERP implementation gap begins. A 2025 MIT study shows that, despite considerable investment, around 95 per cent of corporate technology initiatives generate no measurable impact on results. Our experience from more than 30 years of ERP consulting: this risk is greatest in growth and transition phases — when a company expands its business model before its processes have grown with it.
The obvious route would have been to buy an ERP system that offers "product tracking" as a feature. A vendor-driven selection would have delivered exactly that — a system, but not a process. Because the bottleneck was never the missing software; it was that the process the software could have mapped simply did not yet exist.
This is the heart of our principle "Organisation before IT": an ERP system can only automate what has first been defined as a process. Reverse the order and you invest in technology, then wonder why the productivity never comes. The implementation gap does not open when the software contract is signed — it opens before that, in the undefined process.
The approach therefore followed a clear sequence:
Transparency note: The new integrated ERP system is live and has been accepted. We are monitoring the target corridors and will publish the actual figures after twelve months as a follow-up to this case study.